Spots Global Cancer Trial Database for immunoglobulin g1 kappa subclass
Every month we try and update this database with for immunoglobulin g1 kappa subclass cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | NCT05883644 | Advanced Hepato... | Durvalumab Tremelimumab | 18 Years - 130 Years | AstraZeneca | |
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | NCT05883644 | Advanced Hepato... | Durvalumab Tremelimumab | 18 Years - 130 Years | AstraZeneca |